TNFSF9 and metastatic neoplasm: While PRAME is a driver for genomic instability and recognized as a strong predictor for metastasis for metastatic disease [27, 28], the expression of TNFSF9 is significantly higher in PRAME positive GEP class 2 tumors (Fig. 4C).